ICAN has developed a revolutionary clinical trials search engine called Remission Coach® which is in the final stages of development. That system will tremendously help both patient recruitment and retention in clinical trials.
We are very intent at ICAN to integrate the sophisticated patient voice and patient advocate voice onto the biopharmaceutical industry’s protocol review committees at the earliest stage of their work. Pharmaceutical and biotech companies will certainly save many millions of dollars if patient engagement happens early on. This is also the focus that I have working with fellow patient advocates at the DIA (Drug Information Association) Patient Engagement Community—advocating the actual insertion of the patient and patient advocate voice at every pivot point of the research continuum. If we can do a better job getting the patient voice and patient advocate voice heard earlier rather than later, the global oncology community will benefit from better clinical trials recruitment and retention stats.
ICAN is working to improve recruitment and retention in clinical trials for underserved patient populations.
We think it is critical to have far more trials to meet the need of patients battling rare cancers, and for rare sarcomas and appendix cancer in particular, we want to see additional clinical trial
